2021 Scientific Programme

Highlights

Through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations, the Scientific Programme examines a range of gastrointestinal malignancies and offers a mix of dynamic education and exchange.

  • Cancer of the Pancreas
    • Genetics and molecular alterations in pancreatic cancer
    • Are we making progress in surgery of the pancreas?
    • Adjuvant and neoadjuvant treatment options in resectable and borderline resectable pancreatic cancer
    • Treatment approaches in locally advanced unresectable pancreatic cancer
    • Improving the outcomes of patients with metastatic pancreatic cancer
       
  • Bile Duct Cancer
    • Molecular alterations in bile duct cancer
    • New agents and strategies on the horizon in bile duct cancer
    • The management of locally advanced bile duct cancer
       
  • Meet the Expert Presentations
    • New endoscopic diagnostic and therapeutic technique screening tools: NBI, chromoendoscopy, and other options - How do they help us?
    • Advances in surgery of rectal cancer
    • New developments in radiation oncology
    • Progress in anal cancer
    • Carcinoma of unknown origin
    • How to classify NETs and NECs?
    • Progress in GIST
    • What to do with a malignant colon and rectal polyp?

      ESMO Session: Focus on Young Medical Oncologists
       
  • New Concepts in Clinical Trials and Therapeutics
    • Clinical interpretation and validity of clinical trials: When do they become practice-changing?
    • Gender and race concepts in clinical trials
    • Tumor agnostic trials and approaches
    • Studying value and health economics
    • Studying biosimilars: What is needed and what is the role of biosimilars?
       
  • Esophageal and Gastric Cancers
    • Unraveling the molecular taxonomy in esophageal and gastric cancer
    • Barrett's esophagus: Role of advanced endoscopy in the diagnosis and treatment
    • Management of squamous cell cancer of the esophagus
    • Definitive CRT or neoadjuvant therapy followed by surgery in esophageal cancer
    • Locally advanced GE junction cancer: CRT or perioperative CT
    • Surgery in oligometastatic gastric cancer?
    • Where are we with checkpoint inhibitors in metastatic gastric cancer?
    • New targeted agents in metastatic gastric cancer
       
  • Relevant Pathways in GI Cancer: How Relevant and How to Approach Them?
    • The HER2 pathway
    • The FGFR pathway
    • Protein fusions in GI cancers
    • NGS testing for all patients with GI cancers?
       
  • Hepatocellular Carcinoma
    • How to integrate new agents in HCC
    • Locoregional treatment for HCC
    • Liver transplantation for HCC
    • Multidisciplinary tumor board on HCC
       
  • Expert Highlights: What is New in this Disease in 2021?
    • What is new in NETs?
    • What is new in anal cancer?
    • What is new in bile duct cancer?
       
  • Prevention and Screening of Colon Cancer
    • Genetic testing for familial and hereditary colorectal cancer
    • Screening for colon cancer: What has been achieved in 2021 and new prospects?
    • Will chemoprevention become a reality?
       
  • Multimodality Therapy for Rectal Cancer
    • Imaging in rectal cancer
    • Rectal cancer after neoadjuvant therapy with complete clinical response: Surgery or watchful waiting
    • New prospects in rectal cancer surgery
    • Adjuvant chemotherapy or neoadjuvant chemotherapy in rectal cancer
    • Total neoadjuvant treatment in rectal cancer
    • A role for neoadjuvant chemotherapy without radiotherapy
    • The strategy in synchronous liver metastases of rectal cancer
       
  • Molecular Biology in CRC
    • How to approach a patient with BRAF mutant tumor?
    • Current status and perspectives on liquid biopsies in GI cancer
    • Is circulating tumor DNA relevant in stage II colon cancer?
    • Will microresidual disease assessed by circulating tumor DNA become the new decision indicator of adjuvant treatment?
    • Practical implications of the molecular and immunologic classifications in CRC
    • Is broad NGS testing useful in my patients with metastatic colorectal cancer?
       
  • Keynote Lectures
    • The microbiome in GI cancers
    • Novel immuno-oncology mechanisms and approaches in GI cancers: Where are we?
    • Should DPD deficiency be searched before starting 5FU?
    • Relevant drug interactions in GI oncology
    • How to look for minimal residual disease
       
  • Multidisciplinary Tumor Boards
    • Molecular and hereditary tumor board
    • The challenging patient with HCC
    • The challenging patient with colorectal cancer
       
  • Immune Mechanisms and Immune Therapy in GI Cancer
    • How to improve the results with IO agents in MSI GI cancer
    • Biomarkers for checkpoint inhibitors in GI cancer
    • How can we increase the immunogenicity in MSS CRC?
    • Are we making progress with IO in pancreatic cancer?
    • The link between the immune microenvironment and outcome in colorectal cancer
       
  • Colorectal Cancer
    • Endoscopic treatment of small lesions
    • Updates on treatment algorithms in metastatic CRC in 2021
    • Chemorefractory colorectal cancer
    • Can we refine the selection for adjuvant treatment in stage II colon cancer?
    • Can we refine the selection for adjuvant treatment in stage III colon cancer?
       
  • Clinical Updates
    • When and how to select for debulking and HIPEC in peritoneal carcinomatosis
    • Liver resection of liver metastases
    • Role of robotic surgery